<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(3)</volume><submitter>van den Worm SH</submitter><pubmed_abstract>Severe acute respiratory syndrome (SARS) is a zoonotic disease caused by SARS-related coronavirus (SARS-CoV) that emerged in 2002 to become a global health concern. Although the original outbreak was controlled by classical public health measures, there is a real risk that another SARS-CoV could re-emerge from its natural reservoir, either in its original form or as a more virulent or pathogenic strain; in which case, the virus would be difficult to control in the absence of any effective antiviral drugs or vaccines. Using the well-studied SARS-CoV isolate HKU-39849, we developed a vaccinia virus-based SARS-CoV reverse genetic system that is both robust and biosafe. The SARS-CoV genome was cloned in separate vaccinia virus vectors, (vSARS-CoV-5prime and vSARS-CoV-3prime) as two cDNAs that were subsequently ligated to create a genome-length SARS-CoV cDNA template for in vitro transcription of SARS-CoV infectious RNA transcripts. Transfection of the RNA transcripts into permissive cells led to the recovery of infectious virus (recSARS-CoV). Characterization of the plaques produced by recSARS-CoV showed that they were similar in size to the parental SARS-CoV isolate HKU-39849 but smaller than the SARS-CoV isolate Frankfurt-1. Comparative analysis of replication kinetics showed that the kinetics of recSARS-CoV replication are similar to those of SARS-CoV Frankfurt-1, although the titers of virus released into the culture supernatant are approximately 10-fold less. The reverse genetic system was finally used to generate a recSARS-CoV reporter virus expressing Renilla luciferase in order to facilitate the analysis of SARS-CoV gene expression in human dendritic cells (hDCs). In parallel, a Renilla luciferase gene was also inserted into the genome of human coronavirus 229E (HCoV-229E). Using this approach, we demonstrate that, in contrast to HCoV-229E, SARS-CoV is not able to mediate efficient heterologous gene expression in hDCs.</pubmed_abstract><journal>PloS one</journal><pagination>e32857</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3296753</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination.</pubmed_title><pmcid>PMC3296753</pmcid><pubmed_authors>Davidson AD</pubmed_authors><pubmed_authors>Eriksson KK</pubmed_authors><pubmed_authors>Zust R</pubmed_authors><pubmed_authors>Kuri T</pubmed_authors><pubmed_authors>Dijkman R</pubmed_authors><pubmed_authors>Siddell SG</pubmed_authors><pubmed_authors>Zevenhoven JC</pubmed_authors><pubmed_authors>Thiel V</pubmed_authors><pubmed_authors>van den Worm SH</pubmed_authors><pubmed_authors>Weber F</pubmed_authors><pubmed_authors>Chang G</pubmed_authors><pubmed_authors>Snijder EJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination.</name><description>Severe acute respiratory syndrome (SARS) is a zoonotic disease caused by SARS-related coronavirus (SARS-CoV) that emerged in 2002 to become a global health concern. Although the original outbreak was controlled by classical public health measures, there is a real risk that another SARS-CoV could re-emerge from its natural reservoir, either in its original form or as a more virulent or pathogenic strain; in which case, the virus would be difficult to control in the absence of any effective antiviral drugs or vaccines. Using the well-studied SARS-CoV isolate HKU-39849, we developed a vaccinia virus-based SARS-CoV reverse genetic system that is both robust and biosafe. The SARS-CoV genome was cloned in separate vaccinia virus vectors, (vSARS-CoV-5prime and vSARS-CoV-3prime) as two cDNAs that were subsequently ligated to create a genome-length SARS-CoV cDNA template for in vitro transcription of SARS-CoV infectious RNA transcripts. Transfection of the RNA transcripts into permissive cells led to the recovery of infectious virus (recSARS-CoV). Characterization of the plaques produced by recSARS-CoV showed that they were similar in size to the parental SARS-CoV isolate HKU-39849 but smaller than the SARS-CoV isolate Frankfurt-1. Comparative analysis of replication kinetics showed that the kinetics of recSARS-CoV replication are similar to those of SARS-CoV Frankfurt-1, although the titers of virus released into the culture supernatant are approximately 10-fold less. The reverse genetic system was finally used to generate a recSARS-CoV reporter virus expressing Renilla luciferase in order to facilitate the analysis of SARS-CoV gene expression in human dendritic cells (hDCs). In parallel, a Renilla luciferase gene was also inserted into the genome of human coronavirus 229E (HCoV-229E). Using this approach, we demonstrate that, in contrast to HCoV-229E, SARS-CoV is not able to mediate efficient heterologous gene expression in hDCs.</description><dates><release>2012-01-01T00:00:00Z</release><publication>2012</publication><modification>2021-02-19T09:21:26Z</modification><creation>2019-03-26T23:18:28Z</creation></dates><accession>S-EPMC3296753</accession><cross_references><pubmed>22412934</pubmed><doi>10.1371/journal.pone.0032857</doi></cross_references></HashMap>